Cowen Prime Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Cowen Prime Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-800	Closed	-$322K	–	220
2016 Q3	$322K	Buy	+800	New	+$321K	0.15%	85
2015 Q4	–	Sell	-600	Closed	-$279K	–	249
2015 Q3	$279K	Buy	600 +500	+500%	+$269K	0.13%	85
2015 Q2	$51K	Sell	100 -900	-90%	-$439K	0.02%	159
2015 Q1	$451K	Buy	1,000 +500	+100%	+$212K	0.19%	75
2014 Q4	$205K	Hold	500	–	–	0.08%	115
2014 Q3	$180K	Buy	+500	New	+$168K	0.08%	111
2014 Q2	–	Sell	-1,000	Closed	-$300K	–	286
2014 Q1	$300K	Hold	1,000	–	–	0.11%	75
2013 Q4	$275K	Hold	1,000	–	–	0.11%	85
2013 Q3	$313K	Hold	1,000	–	–	0.12%	87
2013 Q2	$230K	Buy	+1,000	New	+$233K	0.1%	101

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Cowen Prime Advisors's REGN Position: Q4 2016 in Review

Cowen Prime Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2016, closing a stake of 800 shares — an estimated $322K sold.

Cowen Prime Advisors first reported a position in REGN in Q2 2013 and held it in 10 quarters. The position peaked at $451K in Q1 2015. 576 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

Cowen Prime Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Cowen Prime Advisors sold 800 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $322K.
Cowen Prime Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Cowen Prime Advisors's Regeneron Pharmaceuticals position peaked at $451K in Q1 2015.
576 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on Cowen Prime Advisors's 13F filing for Q4 2016, filed 9 Feb 2017.